CMP : 733
Target Price : 877
Aurobindo Pharma (APL) posted numbers lower than expected on sales and net
profit front, while OPM was more or less in line with expectations. On sales front,
the company posted sales of Rs3715cr vs. Rs3,900cr expected vs. Rs3,280cr in
2QFY2016, posting a yoy growth of 13.3%. On the operating front, the EBITDA
margin came in at 23.4% vs. ..